RBC Europe’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $729K | Hold |
5,000
| – | – | 0.04% | 121 |
|
|
2022
Q1 | $816K | Hold |
5,000
| – | – | 0.03% | 118 |
|
|
2021
Q4 | $848K | Buy |
5,000
+855
| +21% | +$145K | 0.04% | 120 |
|
|
2021
Q3 | $783K | Hold |
4,145
| – | – | 0.03% | 161 |
|
|
2021
Q2 | $703K | Sell |
4,145
-4,000
| -49% | -$678K | 0.03% | 178 |
|
|
2021
Q1 | $1.15M | Hold |
8,145
| – | – | 0.06% | 132 |
|
|
2020
Q4 | $1.06M | Hold |
8,145
| – | – | 0.06% | 133 |
|
|
2020
Q3 | $1.19M | Buy |
8,145
+950
| +13% | +$138K | 0.08% | 120 |
|
|
2020
Q2 | $1.07M | Sell |
7,195
-1,000
| -12% | -$148K | 0.08% | 120 |
|
|
2020
Q1 | $892K | Sell |
8,195
-3,565
| -30% | -$388K | 0.09% | 108 |
|
|
2019
Q4 | $1.35M | Hold |
11,760
| – | – | 0.12% | 100 |
|
|
2019
Q3 | $946K | Hold |
11,760
| – | – | 0.09% | 121 |
|
|
2019
Q2 | $853K | Buy |
11,760
+2,500
| +27% | +$181K | 0.09% | 126 |
|
|
2019
Q1 | $865K | Buy |
9,260
+500
| +6% | +$46.7K | 0.1% | 121 |
|
|
2018
Q4 | $639K | Buy |
8,760
+1,570
| +22% | +$114K | 0.08% | 129 |
|
|
2018
Q3 | $629K | Buy |
7,190
+5
| +0.1% | +$438 | 0.07% | 140 |
|
|
2018
Q2 | $708K | Buy |
7,185
+1,040
| +17% | +$102K | 0.08% | 133 |
|
|
2018
Q1 | $732K | Buy |
6,145
+645
| +12% | +$76.8K | 0.09% | 128 |
|
|
2017
Q4 | $699K | Sell |
5,500
-1,500
| -21% | -$191K | 0.09% | 130 |
|
|
2017
Q3 | $822K | Buy |
+7,000
| New | +$822K | 0.11% | 118 |
|